In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 3: Chronic Heart Failure – Pathophysiology and Mechanisms
Session

Event : Heart Failure 2019

Topic : Other

  • Session type : Poster Session
  • Date : 27 May 2019
  • Time : 10:30 - 20:00

42 presentations in this session

Endomyocardial injections of autologous mesenchymal stem cell for treatment the patients with non-ischemic cardiomyopathy

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Kurlianskaya (Minsk,BY)

Altered number of apoptotic-modified endothelial cells originated micro vesicles predict phenotypes of heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Berezin (Zaporizhzhya,UA)

The plastics of atrioventricular valve in patients with chronic heart failure and severe left ventricular dysfunction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : O Shatova (Minsk,BY)

Population pharmacokinetics and pharmacodynamics of vericiguat in heart failure patients with reduced ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Meyer (Wuppertal,DE)

Slow and steady wins the race- the managment of tachycardia induced cardiomyopathy

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : C Farrell (Letterkenny,IE)

Higher levels of ferritin as a predictor of improvement of left ventricular ejection fraction in recent-onset idiopathic dilated cardiomyopathy

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Giraldez Valpuesta (Seville,ES)

Importance of serum sodium in ischemic heart failure with systolic dysfunction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Bansal (New Delhi,IN)

Influence of decompensated heart failure on cardiac acoustic biomarkers: impact on early readmissions

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : JW Erath (Frankfurt A. M.,DE)

Two-years effect of cardiac contractility modulation on reverse left ventricular remordeling in patients with heart failure and sinus rhythm

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Sitnikova (St-Petersburg,RU)

Gut microbiome and heart failure with reduced ejection fraction in patients with coronary artery disease

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : E Sawicka (Bialystok,PL)

Characteristics of heart failure patients treated with sacubitril/valsartan in the province of Quebec, Canada

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Daoust (Dorval,CA)

Latino american experience with Sacubitril/Valsartan in a heart failure unit : Real insight

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Rodriguez (Bogota,CO)

Heart failure hospitalization in patients with reduced ejection fraction in a heart failure clinic

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Seabra (Vila Do Conde,PT)

Correlation of nutritional status with chosen biochemical parameters in patients hospitalized due to heart failure with reduced ejection fraction.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : H Krysztofiak (Zielona Gora,PL)

VO2 recovery delay is a useful predictor for impaired recovery of left ventricular function in heart failure with reduced ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : K Chun (Seoul,KR)

Heart failure with mid-range ejection fraction: a distinct entity or rather a transitional phase?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Stassen (Hasselt,BE)

Clinical and echocardiographic phenotypes of patients with postinfarction cardiosclerosis: focus on patients with heart failure with mid-range ejection fraction.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Kuular (Saint Petersburg,RU)

One year follow-up of clinical and mortality data of heart failure patients with mid-range ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Szabo (Budapest,HU)

Prognosis value of the mini nutritional assessment short form tool in outpatients with heart failure with mid-range ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M De Antonio Ferrer (Barcelona,ES)

Is the obesity paradox also present in heart failure with mid-range ejection fraction?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Lupon (Badalona,ES)

Characteristics of LV left ventricular myocardium remodeling in patients with acute decompensated heart failure and intermediate LV left ventricular ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : EG Skorodumova (Saint Petersburg,RU)

Heart failure with mid-range ejection fraction in southern Brazil: an eight year follow up cohort

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : LC Danzmann (Porto Alegre,BR)

Profile and differential management of patients with a mid-range ejection fraction compared to patients with depressed ejection fraction, long-term follow-up

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Enriquez Vazquez (Lugo,ES)

On mid-term, had mid-range ejection fraction heart failure the same prognosis with reduced ejection fraction heart failure?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : CM Goidescu (Cluj Napoca,RO)

Influence of left ventricular ejection fraction category in patients with stenosis aortic undergoing with transcatheter aortic valve replacement

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Munoz-Garcia (Malaga,ES)

Mid range ejection fraction: a continuum or a self clinical entity?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : CL Gonzalez (Ciudad Autonoma De Buenos Aire,AR)

Sexual differences in heart failure with mid-range ejection fraction patients

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : JC Choe (Busan,KR)

The role of inflammation and fibrosis in the occurrence of atrial fibrillation in heart failure patients with mid-range ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Grigoryan (Yerevan,AM)

The significance of blood pressure control in heart failure with mid-range ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Marketou (Heraklio,GR)

Adherence to therapy in patients with heart failure with mid-range ejection fraction: a problem to solve

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : L Popescu (Bucuresti,RO)

Haemodynamic differences in response to physiological and pharmacological stress in heart failure with preserved ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Sengupta (Nagpur,IN)

Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : T Haider (Zurich,CH)

Peak VO2 as a main determinant of health related quality of life in symptomatic patients with heart failure with preserved ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : B Ventura Perez (Vila-Real,ES)

Characteristics and outcomes of HFpEF with declining ejection fraction

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Park (Seongnam,KR)

Incidence and probability of heart failure with preserved ejection fraction among high risk hypertensive patients.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : K Gudieva (Moscow,RU)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are